Allergy to Omalizumab: Lessons from a Reaction to the Coronavirus 2019 Vaccine-Reference-Cited by-同舟云学术

Allergy to Omalizumab: Lessons from a Reaction to the Coronavirus 2019 Vaccine

Published:2023-04-15 Issue:8 Volume:62 Page:1219-1222
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Matsumoto Takeshi¹,Sakurai Yumiko²,Fujiki Takahiro¹,Kusakabe Yusuke¹,Nakayama Emi¹,Tanaka Ayaka¹,Yamamoto Naoki¹,Aihara Kensaku¹,Yamaoka Shinpachi¹,Mishima Michiaki¹

Affiliation:

1. Department of Respiratory Medicine, Saiseikai-Noe Hospital, Japan

2. Department of Dermatology, Saiseikai-Noe Hospital, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/62/8/62_1169-22/_pdf

Reference18 articles.

1. 1. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60: 309-316, 2005.

2. 2. Cox L, Platts-Mills TAE, Finegold I, Schwartz LB, Simons FER, Wallace DV. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 120: 1373-1377, 2007.

3. 3. Kim HL, Leigh R, Becker A. Omalizumab: practical considerations regarding the risk of anaphylaxis. Allergy Asthma Clin Immunol 6: 32, 2010.

4. 4. Bergmann KC, Maurer M, Church MK, Zuberbier T. Anaphylaxis to mepolizumab and omalizumab in a single patient: is polysorbate the culprit? J Investig Allergol Clin Immunol 30: 285-287, 2020.

5. 5. Perino E, Freymond N, Devouassoux G, Nicolas JF, Berard F. Xolair-induced recurrent anaphylaxis through sensitization to the excipient polysorbate. Ann Allergy Asthma Immunol 120: 664-666, 2018.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A risk of serious anaphylatic reactions to asthma biologics: a pharmacovigilance study based on a global real-world database;Scientific Reports;2023-10-17

2. Long-Term Safety of Omalizumab in Children with Asthma and/or Chronic Spontaneous Urticaria: A 4-Year Prospective Study in Real Life;Journal of Personalized Medicine;2023-06-29

3. Multiple drugs;Reactions Weekly;2023-05-20